Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Try Now for Just $1!

DCPH Company Profile and Key Details

NASDAQ : DCPH

Deciphera Pharmaceuticals, Inc.

$25.59
0.02+0.08%
Open: 4:00 PM
Not Actively Trading
58.85
BESG ScoreESG Rating
ProfileKey StatsAnalyst RatingsOwnershipRatiosFinancialsDividend & splitsSentimentForecast

Price Chart

Stock Price Today

Deciphera Pharmaceuticals, Inc. (DCPH) stock surged +0.08%, trading at $25.59 on NASDAQ, up from the previous close of $25.57. The stock opened at $25.56, fluctuating between $25.56 and $25.61 in the recent session.

Stock Snapshot

25.57
Prev. Close
25.56
Open
2.21B
Market Cap
86.48M
Number of Shares
25.56
Day Low
25.61
Day High
-11.57918552036199
P/E Ratio
53.69%
Free Float in %
-2.21
EPS (TTM)
4.05
Book Value
-1.7
Cash Flow per Share
1.57M
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Jun 11, 202425.5925.5925.5925.590
Jun 10, 202425.5625.6125.5625.591.59M
Jun 07, 202425.5725.5825.5625.57506.79K
Jun 06, 202425.5825.5825.5525.551.22M
Jun 05, 202425.5725.5925.5525.582.01M
Jun 04, 202425.5625.5725.5525.57510.52K
Jun 03, 202425.5625.5725.5425.561.42M
May 31, 202425.5225.5625.5225.541.85M
May 30, 202425.5325.5425.5125.53701.01K
May 29, 202425.5125.5325.5125.511.06M
May 28, 202425.5225.5425.5125.511.09M
May 24, 202425.5225.5325.5125.51553.79K
May 23, 202425.5225.5225.4925.501.06M
May 22, 202425.5325.5325.4725.481.76M
May 21, 202425.4625.4925.4625.471.08M
May 20, 202425.4725.4825.4525.47851.18K
May 17, 202425.4625.4725.4425.461.15M
May 16, 202425.4625.4625.4325.451.43M
May 15, 202425.4725.4825.4425.45970.46K
May 14, 202425.4425.4725.4025.444.96M

Contact Details

Waltham, MA 02451

United States

Website: https://www.deciphera.comContact: 781 209 6400

About Company

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Company Information

Employees355
Beta0.18
Sales or Revenue$163.36M
5Y Sales Change%0%
Fiscal Year EndsDecember
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Frequently Asked Questions

What is the current Deciphera Pharmaceuticals, Inc. (DCPH) stock price?
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) stock price is $25.59 in the last trading session. During the trading session, DCPH stock reached the peak price of $25.61 while $25.56 was the lowest point it dropped to. The percentage change in DCPH stock occurred in the recent session was 0.08% while the dollar amount for the price change in DCPH stock was $0.02.
DCPH's industry and sector of operation?
The NASDAQ listed DCPH is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Deciphera Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of DCPH?
Dr. Daniel L. Flynn Ph.D.
Executive Vice President, Chief Scientific Officer & Founder
Mr. Steven L. Hoerter
Pres, Chief Executive Officer & Director
Dr. Stephen B. Ruddy Ph.D.
Senior Vice President & Chief Technical Officer
Mr. Thomas Patrick Kelly J.D.
Executive Vice President, Chief Financial Officer & Treasurer
Jennifer Larson
Senior Vice President of Fin. & Investor Relations
Mr. Jeffrey M. Held J.D.
Senior Vice President & Gen. Counsel
Dr. Matthew L. Sherman M.D.
Executive Vice President & Chief Medical Officer
Mr. Daniel C. Martin
Senior Vice President & Chief Commercial Officer
Ms. Jama Pitman
Senior Vice President of Regulatory, Quality & Portfolio Management
How DCPH did perform over past 52-week?
DCPH's closing price is 158.49% higher than its 52-week low of $9.90 where as its distance from 52-week high of $25.61 is -0.08%.
How many employees does DCPH have?
Number of DCPH employees currently stands at 355.
Link for DCPH official website?
Official Website of DCPH is: https://www.deciphera.com
How do I contact DCPH?
DCPH could be contacted at phone 781 209 6400 and can also be accessed through its website. DCPH operates from 200 Smith Street, Waltham, MA 02451, United States.
How many shares of DCPH are traded daily?
DCPH stock volume for the day was 1.57M shares. The average number of DCPH shares traded daily for last 3 months was 1.86M.
What is the market cap of DCPH currently?
The market value of DCPH currently stands at $2.21B with its latest stock price at $25.59 and 86.48M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

HomeAboutMeet The TeamContact UsPrivacy PolicyNewsletter

Useful Links

ScreenerMarket DataInsider TransactionsUpgrades & Downgrades52 Week Highs & LowsUnusual VolumeDividend CalendarEarnings Calendar
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph